Respiratory Services, Auckland District Health Board, Auckland, New Zealand.
Respirology. 2012 Feb;17(2):285-90. doi: 10.1111/j.1440-1843.2011.02066.x.
We hypothesized that the prevalence of allergic disorders, characterized by the release of type 2 cytokines (IL-4, IL-5, IL-10), would be lower in sarcoidosis in which there is a dominant type 1 immune response (IL-2, interferon-gamma). The objective was to measure the prevalence of atopy and self-reported asthma in patients with sarcoidosis.
Sarcoidosis patients (n = 136, 72 M, age range 22-75), recruited in the outpatient setting, completed a modified European Community Respiratory Health Survey. 123 of these patients provided blood for allergy testing.
For the cohort as a whole the self-reported prevalence of asthma ever (21.5%) and asthma attack in the last 12 months (7.5%), was high as was wheezing (42.1%), breathlessness with wheeze (22.3%) and use of an asthma medication (13.1%). The prevalence of atopy was 34%. These data are not different from the previously reported prevalence of asthma and atopy in New Zealand.
The same prevalence of asthma symptoms and atopy as in the normal population suggests that the immune system is not skewed away from mounting T helper type 2 immune responses in sarcoidosis.
我们假设，在以 1 型免疫反应（IL-2、干扰素-γ）为主导的结节病中，以释放 2 型细胞因子（IL-4、IL-5、IL-10）为特征的过敏疾病的患病率会更低。目的是测量结节病患者中特应性和自述哮喘的患病率。
在门诊环境中招募了 136 名结节病患者（72 名男性，年龄 22-75 岁），他们完成了改良的欧洲社区呼吸健康调查。其中 123 名患者提供血液进行过敏测试。
对于整个队列，自述过去有哮喘（21.5%）和过去 12 个月内哮喘发作（7.5%）的患病率很高，气喘（42.1%）、伴有气喘的呼吸困难（22.3%）和使用哮喘药物（13.1%）的患病率也很高。特应性的患病率为 34%。这些数据与新西兰先前报道的哮喘和特应性患病率没有差异。
与正常人群相同的哮喘症状和特应性患病率表明，结节病患者的免疫系统不会偏向于产生 T 辅助 2 型免疫反应。
